Johnson & Johnson proposes to pay $6.5B to settle talc ovarian cancer lawsuits in US

Dr. Corinne Le Goff, President and CEO of Imunon, explains a breakthrough in ovarian cancer research which uses technology to make cancer fighting molecules in humans. Johnson & Johnson on Wednesday proposed a plan to pay nearly $6.5 billion to resolve tens of thousands of lawsuits claiming that its cosmetic talc-based powder causes cancer.  Through a bankruptcy filing of its subsidiary…